Biolight Life Sciences

Biolight Life Sciences FCF Margin

The Free Cash Flow Margin of Biolight Life Sciences (BOLT.TA) as of Nov 5, 2026 is -5,032.88 %. In the previous year, Free Cash Flow Margin was -9,315.25 % — a change of -45.97% (higher).

FCF Margin

-5,032.88 %

YoY

-45.97%

Last updated:

Free Cash Flow Margin of Biolight Life Sciences is 2024 -5,032.88 % . Free Cash Flow Margin of Biolight Life Sciences was 2023 -9,315.25 % . It decreases by -45.97% higher compared to the previous year.

The Biolight Life Sciences FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2017
-2,103.80 ILS
Jan 1, 2018
-608.73 ILS
Jan 1, 2019
-5,180.47 ILS
Jan 1, 2020
-43,529.03 ILS
Jan 1, 2021
-355,066.67 ILS
Jan 1, 2022
-15,298.41 ILS
Jan 1, 2023
-9,315.25 ILS
Jan 1, 2024
-5,032.88 ILS
The Biolight Life Sciences FCF Margin history
YEARFCF MarginYoY
-5,032.88 %-45.97%
-9,315.25 %-39.11%
-15,298.41 %-95.69%
-355,066.67 %+715.70%
-43,529.03 %+740.25%
-5,180.47 %+751.02%
-608.73 %-71.07%
-2,103.80 %+62.61%
-1,293.79 %-25.69%
-1,741.12 %-40.18%
-2,910.63 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biolight Life Sciences Stock analysis

What does Biolight Life Sciences do? Biolight Life Sciences Ltd is a global company specializing in the development, production, and marketing of medical devices and products. It was founded in China in 1993 and has since relocated its headquarters to Israel. Biolight has evolved from a small company to a leading provider of medical devices and products that help improve patient treatment and optimize healthcare. The company's business model is based on selling medical devices and products used in diagnosis, monitoring, and treatment of patients. It continually strives to improve its products through research and development to enhance healthcare worldwide. Biolight believes that cooperative technologies and services can create synergistic value that benefits patients. Its various divisions include monitoring and diagnostic devices, cardiology products, and emergency medicine products. Biolight offers a wide range of products to ensure quality healthcare. Its monitoring and diagnostic devices measure various physiological parameters such as blood pressure, heart rate, respiration, oxygen saturation, and temperature. The cardiology products are tailored to the needs of heart patients and include EKG devices, long-term EKG systems, and Holter devices. The emergency medicine products treat life-threatening conditions such as heart attacks, strokes, and respiratory distress, thereby saving lives. To ensure a high-quality healthcare system, it is essential for medical devices and products to meet the highest standards. Biolight is aware of this and is committed to offering products that comply with the strictest international quality standards such as ISO 13485, CE, and FDA. Biolight has a broad global presence with branches and subsidiaries in numerous countries such as the USA, China, India, Germany, Spain, and France. This global presence enables the company to understand and meet the needs of patients and medical personnel in different parts of the world. Biolight also collaborates with partners and customers to further improve its products and services and meet market demands. Overall, Biolight has made a sustainable contribution to improving healthcare. Through its continuous research and development, products and services, and global presence, the company has established itself as a key player in the medical technology industry. By working with partners and customers, Biolight can contribute to ensuring that patients worldwide have access to the best healthcare. Biolight Life Sciences is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biolight Life Sciences stock

Free Cash Flow Margin of Biolight Life Sciences is -5,032.88 % in 2024.

Free Cash Flow Margin of Biolight Life Sciences changed from -9,315.25 % to -5,032.88 %, representing a -45.97% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin Biolight Life Sciences since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's Biolight Life Sciences with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Biolight Life Sciences

All Key Metrics — Biolight Life Sciences